(Sharecast News) - Molecular diagnostics company Yourgene Health saw top-line growth over the six months ended 30 September as international revenues continued to show "very strong momentum".
Yourgene's sales soared 98% year-on-year to £7.8m, in line with management expectations, with Elucigene Diagnostics, acquired back in April, contributing primarily to UK and European sales growth.
International revenues also included the AIM-listed group's first sales from the US. Organic growth, excluding contributions from the Elucigene acquisition, came to 56%.
Yourgene said on Monday that revenues were now showing greater diversity - with 20% derived from reproductive health products generated by the acquired Elucigene Diagnostics and 17% derived from its "rapidly growing" oncology and research services activities in Asia.
Yourgene also stated that revenues from non-invasive prenatal testing products and services grew 34% across all markets.
Chief executive Lyn Rees said: "I am delighted with the performance in the first half, both in terms of the organic growth delivered but also the contribution from the Elucigene acquisition and the launch of our American business.
"We are executing on our strategy to broaden our product portfolio and to drive growth across wider international markets. We remain on track to hit our ambitious growth targets for the enlarged group and to meet market expectations for the full year."
As of 0845 BST, Yourgene shares had climbed 5.57% to 12.14p.
9 Jun 2021 09:58
Yourgene inks agreement with US-based precision medicine company
(Sharecast News) - Molecular diagnostics group Yourgene has inked a licence and supply agreement with an unnamed American precision medicine company.
Read more